Convergent dysregulation of frontal cortical cognitive and reward systems in eating disorders

1,2 George B. Stefano
1 Radek Ptáček
1,3 Hana Kuželová
2 Kirk J Mantione
1 Jiří Raboch
1 Hana Papezova
1,2 Richard M. Kream

Corresponding Author: George B Stefano, e-mail: gstefano@sunynri.org

Source of support: Self financing

A substantive literature has drawn a compelling case for the functional involvement of mesolimbic/prefrontal cortical neural reward systems in normative control of eating and in the etiology and persistence of severe eating disorders that affect diverse human populations. Presently, we provide a short review that develops an equally compelling case for the importance of dysregulated frontal cortical cognitive neural networks acting in concert with regional reward systems in the regulation of complex eating behaviors and in the presentation of complex pathophysiological symptoms associated with major eating disorders. Our goal is to highlight working models of major eating disorders that incorporate complementary approaches to elucidate functionally interactive neural circuits defined by their regulatory neurochemical phenotypes. Importantly, we also review evidence-based linkages between widely studied psychiatric and neurodegenerative syndromes (e.g., autism spectrum disorders and Parkinson’s disease) and co-morbid eating disorders to elucidate basic mechanisms involving dopaminergic transmission and its regulation by endogenously expressed morphine in these same cortical regions.

Key words: cognition • reward systems• eating disorders • frontal cortex • binge eating • bulimia • anorexia • dopamine • morphine

Full-text PDF: http://www.medscimonit.com/download/index/idArt/889133
Background

DSM IV-TR [1] coding and diagnostic criteria list 3 categories of adult eating disorders (EDs): 307.1 Anorexia nervosa; 307.51 Bulimia nervosa; and 307.50 Eating disorder not otherwise specified (EDNOS). Binge eating disorder (BED) is listed in the DSM IV-TR appendix and is often, but not exclusively, linked to obesity. Feeding and eating disorders of infancy or early childhood are listed as 307.52 Pica and 307.53 Rumination Disorder [1]. Recently, Wildes and Marcus have questioned the limitations of operational or symptom-based psychiatric classifications of EDs and have proposed alternative classification into 2 major groups: 1) those based on disordered eating symptoms; and, 2) those based on comorbid psychopathology and associated features [2]. Interestingly, the authors review models of comorbidity-based ED classification incorporating impulsivity, compulsivity, distress, and inhibition vs. risk-taking, with an emphasis on empirical elucidation of basic behavioral and neuropsychological mechanisms underlying these pathophysiological processes.

In light of the above, a substantive literature has drawn a compelling case for the functional involvement of mesolimbic/prefrontal cortical neural reward systems in normative control of feeding and in the etiology and persistence of severe EDs that afflict diverse human populations [3–7]. Herein, we provide a short review that develops an equally compelling case for the importance of dysregulated frontal cortical cognitive neural networks acting in concert with regional reward systems in the regulation of complex feeding behaviors and in the presentation of complex pathophysiological symptoms associated with EDs [8–11]. Our goal is to highlight working models of major EDs that incorporate complementary approaches to elucidate functionally interactive neural circuits define by their regulatory neurochemical phenotypes. Importantly, we also review evidence-based links between widely studied psychiatric and neurodegenerative syndromes (e.g., autism spectrum disorders [12] and Parkinson’s disease [13,14]) and co-morbid EDs to elucidate basic mechanisms involving dopaminergic transmission and its regulation by endogenously expressed morphine in these same cortical regions [15–17].

Anorexia Nervosa and Bulimia Nervosa: Identification of Functionally Linked Frontal Cortical and Limbic Anatomical Loci

A perusal of the neuropsychiatric literature clearly indicates that the establishment of a functional CNS anatomy linked to EDs has been critically dependent upon the application of high-resolution biological imaging techniques to clinical studies of patient cohorts with anorexia nervosa (AN) and bulimia nervosa (BN) over the last decade. A key 2003 study used functional magnetic resonance imaging (fMRI) to monitor alterations in CNS activity subsequent to the presentation of food and emotional visual stimuli in 9 women who experienced long-term recovery from restricting AN [18]. Subject data sets were compared to those derived from matched control groups consisting of healthy women and women chronically ill with restricting AN. Subsequent to presentation of food stimuli, enhanced medial prefrontal and anterior cingulate activation was observed in the brains of recovered AN subjects in comparison to healthy controls, whereas a lack of activity was observed in the inferior parietal lobule of all subjects. Differential activation of the right lateral prefrontal, apical prefrontal, and dorsolateral cingulate cortices was observed in the brains of recovered AN subjects in comparison to chronically ill AN subjects. Interestingly, group differences in fMRI responses were specific to food stimuli and were not observed following presentation of emotional stimuli. The authors concluded that medial prefrontal responses to AN-specific stimuli may be related to trait vulnerability and that lateral and apical prefrontal responses were associated with positive outcomes.

A complementary 2004 study monitored altered CNS activity via fMRI responses in 2 separate groups of female subjects with AN and BN in comparison to healthy controls subsequent to presentation of food and aversive emotional images [19]. Subjects with EDs identified food stimuli as threatening and disgusting and demonstrated enhanced CNS activity in the left medial orbitofrontal and anterior cingulate cortices and diminished activity in the lateral prefrontal cortex, inferior parietal lobule, and cerebellum in comparison to matched controls. Between-group differences in fMRI responses to non-specific emotional stimuli were observed in the occipital cortex, parietal cortex, and cerebellum. Consonant with the prior 2003 study [18], the authors concluded that an enhanced medial prefrontal fMRI in response to symptom-provoking stimuli is a common feature of AN and BN, and that aberrant activation of medial prefrontal circuitry in response to inappropriate stimuli is common to eating, obsessive-compulsive, and addictive disorders.

From a complementary clinical perspective, body image distortion is a defining behavioral symptom in AN patients. Accordingly, a 2003 fMRI study evaluated the effects of digitally distorted body images using a computer-based video-technique on CNS activation patterns in female AN patients in comparison to healthy controls [20]. AN patients demonstrated enhanced activation in the prefrontal cortex and the inferior parietal lobule, including the anterior intraparietal sulcus, in comparison to matched controls. A prior study from this group using the same digitally distorted body image paradigm also monitored enhanced activation in the right amygdala, the right gyrus fusiformis, and brainstem of AN patients [21]. Subsequent validation of these observations indicated...
that considerable variability in subjective emotional reactions to body shape perception in AN and BN patients is associated with differential fMRI activation responses in the prefrontal cortex [22,23] and the amygdala [24]. In reference to the amygdala, significant ‘fat-image’ activation was observed in restricting-type AN patients, in binging-purging type AN patients, and in healthy matched controls, but not in BN patients [24]. In contrast, the prefrontal cortex was significantly activated in binging-purging type AN patients, and in healthy matched controls, but not in restricting-type AN patients and BN patients [24]. The authors conclude that differential CNS activation patterns observed for each ED group may underlie differences in cognitive processing with respect to distorted body image. As summarized in a 2012 review [10], classification of fMRI studies on body image distortion in AN is sorted according to perceptive, affective, and cognitive categories. The perceptive component is mainly related to altered activity of the precuneus and the inferior parietal lobe, whereas the affective component is mainly related to altered activities of the prefrontal cortex, the insula, and the amygdala. The authors contend that elucidation of cognitive components of body image distortion in AN is ongoing and requires further investigation.

Impaired or compromised cognition-derived behavioral flexibility is associated as a trait marker in AN patients and highlights a working model of AN that includes hypoactivation in ventral anterior cingulate- striatothalamic circuitry that is involved in motivation-related behaviors [25,26]. Furthermore, AN patients demonstrate enhanced activation of frontoparietal circuitry that is functionally associated with supervisory control during task performance [25,26]. Importantly, when placed within this conceptual context, working models of EDs share compelling behavioral comorbidities with major neuropsychiatric disorders, including attention-deficit hyperactivity disorder (ADHD) [27,28], major depressive disorder (MDD) [29], schizophrenia [30], and bipolar disorder [31].

Recently, imaging studies have attempted to further characterize ED patient subtypes by differences in behavioral impulsivity linked to neural circuitry associated with inhibitory control mechanisms [32,33]. Additionally, hypoactivation in frontal cortical “theory of mind” brain circuitry has been functionally associated with the presentation of a social-cognitive endophenotype that reflects impaired social functioning in AN patients [34]. Kaye et al recently proposed that complex AN symptomatology is derived from dysregulated neural systems underlying reward and/or awareness of homeostatic needs, in concert with cognitive systems related to enhanced executive ability to inhibit incentive motivational drives [35]. A series of studies from a Swedish research group demonstrated differential neural activation to viewing food images via fMRI analyses in women with AN vs. women with BN [36,37]. The authors conclude that women with AN and BN activate top-down cognitive control in response to food images, yet women with BN have increased activation in reward and somatosensory regions, which might impinge on cognitive control over eating [36,37]. Finally, investigators have recognized overlapping dysregulated cognitive profiles in AN patients in comparison to people with autism spectrum disorders (ASDs) [38]. These observations are complemented by a recent study that demonstrated aberrantly enhanced neural activation in response to food cues in bilateral insula and in the anterior cingulate cortex in people with ASD in comparison to matched healthy controls [12]. Overall, these observations suggest that neural responses in cortical cognitive and primary reward circuitry are convergently dysregulated in AN patients and in subsets of children with ASD.

**Anorexia Nervosa and Bulimia Nervosa: Identification of Functionally Linked Neurochemical Phenotypes, with Special Reference to Comorbid Psychiatric and Neurodegenerative Disorders**

Recent complementary studies using positron emission tomography (PET) and single-photon emission computed tomography with 5-HT-specific radioligands have consistently demonstrated alterations in 5-HT(1A) and 5-HT(2A) receptor and in 5-HT transporter densities in cortical and limbic circuitry of AN and BN patients [39–41]. Alterations of cortical and limbic 5-HT circuits in patients with EDs are proposed to negatively affect mood and impulse control, motivating and hedonic aspects of eating behavior, as well as behavioral inhibition and body image distortions [39–41]. Complementary PET studies have monitored alterations in dopaminergic (DA-ergic) parameters via D2/D3 receptor ligand binding in striatal areas of recovering AN patients [42], and found coordinate alterations of 5-HT transporter dopamine D2/D3 receptor densities in striatal areas of AN and BN patients that are functionally associated with harm avoidance symptomatology [43]. From a different perspective, comorbid EDs classified as impulse control disorders (ICDs) have been observed in cohorts of Parkinson’s disease (PD) patients administered L-DOPA as a CNS DA restorative therapy [14]. Putative validating evidence in support of dysregulated frontal cortical DA as a neurochemical trait phenotype in EDs is provided by a recent PET study demonstrating significantly enhanced [18F]fluorodopa uptake in the medial orbitofrontal cortex of PD patients in comparison to matched controls [13]. The authors conclude that enhanced DA-ergic activity in the medial orbitofrontal cortex may be associated with increased sensitivity or vulnerability to ICDs following DA replacement therapy in PD patients.

We recently reviewed preclinical and clinical studies that support a working mechanistic scheme whereby atypical
antipsychotic drugs ameliorate negative DSM-IV diagnostic criteria in schizophrenic patients by effecting relatively potent blockade of 5-HT(2A) receptors, coupled with weaker antagonism of D(2) receptors in frontal cortical areas [44]. Notably, cognitive disorders represent a hallmark core dysfunction in schizophrenics, with the severity of cognitive symptoms serving as a better indicator of social and functional outcome (i.e., quality of life) than standard measures of antipsychotic drug efficacy via DSM-IV criteria [45]. Cognitive processes that are specifically impaired in schizophrenia are verbal memory, working memory, motor function, attention, executive functions, and verbal fluency. Functional imaging studies indicate that schizophrenic patients fail to activate their frontal cortex following selective cognitive tasks [46,47]. Thus, deficiencies in cognitive measures should be recognized as a major element in social and vocational integration of schizophrenia patients, and should become a standardized assessment approach in clinical trials [48]. As discussed above, overlapping disordered cognitive behavioral profiles of EDs patients with patients who have major psychiatric disorders [27–31] are compelling and support equivalent dysregulation of convergent frontal cortical cognitive and reward neural circuits.

Recently derived neural models of EDs have drawn functional linkages of starvation in AN or binge eating in BN with DA-driven mesolimbic/mesocortical addictive processes [6,49]. Furthermore, it is proposed that executive corticostriatal processes related to extraordinary inhibition and self-control in AN and diminished inhibitory self-control in BN may modulate rewarding aspects of palatable foods as well as other consummatory behaviors. Accordingly, convergent dysregulation of interactive limbic and executive corticostriatal circuitry supports the working hypothesis that reward and inhibitory processes may contribute to comorbid symptomatology observed in major EDs and addictive disorders [49–55].

### Potential Involvement of Monoaminergic Transmission and Its Regulation by Endogenous Morphine in the Frontal Cortical Regions in the Etiology of Major Eating Disorders

For over 30 years empirical studies have repeatedly demonstrated that endogenous morphine is expressed by diverse animal and human tissues. Because the prototype catecholamine DA and its major precursor L-DOPA were also found to be utilized as morphine precursors, a novel reciprocally interactive mechanism is compellingly apparent, which links DA “morphinergic” pathways in the activation and inhibition of behavioral/cognitive responses within discrete cortical regions [56,57]. In support of these contentions, immunohistochemical studies have revealed the presence of morphine-like immunoreactive material in the perikarya, fibers, and terminals of neurons in cortical areas of rat and human brain [58]. Furthermore, a 2011 anatomical study found colocalization of endogenous morphine-like to GABAergic cells in rodent cerebral cortex [59]. We therefore hypothesize that endogenous morphine systems are reciprocally dysregulated in schizophrenia and are intimately linked to major alterations in DA-ergic transmission and DA receptor expression.

We previously presented a case for low-dose morphine as a cognitive enhancer in schizophrenia patients based on functional and behavioral studies of cortical distributions of its type-selective mu opioid receptor in discrete prefrontal and orbitofrontal regions [44]. These contentions are strengthened by complementary human studies of interactive 5-HT(2A) receptor systems in these same cortical areas. A 2011 controlled cross-over human PET study observed significantly enhanced 5-HT(2A) receptor PET ligand binding in the orbitofrontal cortex with the performance of executive functions of working memory, and concluded that 5-HT(2A) receptor systems mediate and optimize basic cognitive functions [60]. A recent imaging study found that schizophrenic patients had significantly lower 5-HT(2A) binding in the frontal cortex than did control subjects [61]. Additionally, cortical 5-HT/5-HT2A receptor activation appears to serve as a functional indicator of CNS dopaminergic transmission via effects on circulating plasma cortisol and prolactin concentrations. Interestingly, complementary biochemical studies have demonstrated reciprocal functional interactions of the 5-HT2A receptor and the mu opioid peptide receptor following activation by morphine [62]. These data suggest that selective activation of the 5-HT2A receptor, in concert with low dose morphine treatment, may mediate positive effects on cognitive processes within the orbitofrontal cortex. Based on multiple studies cited in our short review, it appears that similar functional criteria may be applied to complex cognitive and reward-oriented “morphinergic”/monoaminergic regulatory processes underlying normative eating and satiation and their dysregulation in major EDs.

### Conclusions

We have highlighted formative working models of major EDs that incorporate complementary approaches to elucidate functionally interactive frontal cortical neural circuits in association with their regulatory neurochemical phenotypes. We have also presented evidence-based linkages, (i.e., established co-morbidities) between widely studied psychiatric and neurodegenerative syndromes and EDs. Finally, we have introduced a prospective case for the involvement of basic mechanisms involving DA-ergic/monoaminergic transmission and its regulation by endogenously expressed morphine in these same cortical regions associated with major EDs.
1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 2000

2. Wildes JE, Marcus MD: Alternative methods of classifying eating disorders: Models incorporating comorbid psychopathology and associated features. Clin Psychol Rev, 2013; 33: 383–94

3. Neary MT, Batterham RL: Gaining new insights into food reward with functional neuroimaging. Forum Nutr, 2010; 63: 152–63

4. De Silva A, Salem V, Matthews PM, Dhillo WS: The use of functional MRI to study appetite control in the CNS. Exp Diabetes Res, 2012; 2012: 764017

5. Hollmann M, Heilrg M, Pleger B et al: Neural correlates of the volitional regulation of the desire for food. Int J Obes (Lond), 2012; 36: 648–55

6. Tomasi D, Volkow ND: Striatocortical pathway dysfunction in addiction and obesity: differences and similarities. Crit Rev Biochem Mol Biol, 2013; 48: 1–19

7. Fladung AK, Gron G, Grammer K et al: A neural signature of anorexia nervosa in the ventral striatal reward system. Am J Psychiatry, 2010; 167: 206–12

8. Joseph RI, Alonso-Alonso M, Bond DS et al: The neurocognitive connection between physical activity and eating behaviour. Obes Rev, 2011; 12: 800–12

9. Van den Eynde F, Claudino AM, Campbell IC, Schmidt U: Immediate cognitive effects of repetitive Transcranial Magnetic Stimulation in eating disorders: a pilot study. Eat Weight Disord, 2011; 16: e45–48

10. Gaudio S, Quattrocchi CC: Neural basis of a multidimensional model of body image distortion in anorexia nervosa. Neurosci Biobehav Rev, 2012; 36: 1839–47

11. van KK, Gerard N, Van Le et al: Towards a neurocircuitry in anorexia nervosa: evidence from functional neuroimaging studies. J Psychiatr Res, 2009; 43: 1133–45

12. Cascio CJ, Foss-Feig JH, Heacock JL et al: Response of neural reward regions to food cues in autism spectrum disorders. J Neurodev Disorders, 2012; 4: 9

13. Joutsa J, Martikainen K, Niemela S et al: Increased medial orbitofrontal [18F] fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord, 2012, 27: 778–82

14. Vilas D, Pont-Sunyer C, Tolosa E: Impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord, 2012; 18(Suppl.1): S80–84

15. Kontis D, Theochari E: Dopamine in anorexia nervosa: a systematic review. Behav Pharmacol, 2012; 23: 496–515

16. Stice E, Yokum S, Zald D, Dagher A: Dopamine-based reward circuitry responsivity, genetics, and overeating. Curr Top Behav Neurosci, 2011; 6: 81–93

17. Ziauddeen H, Chamberlain SR, Nathan PJ et al: Effects of the mu-opioid receptor antagonist GSX1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Mol Psychiatry, 2012: [Epub ahead of print]

18. Uher R, Brammer MJ, Murphy T et al: Recovery and chronicity in anorexia nervosa: brain activity associated with differential outcomes. Biol Psychiatry, 2003; 54: 934–42

19. Uher R, Murphy T, Brammer MJ et al: Medial prefrontal cortex activity associated with symptom provocation in eating disorders. Am J Psychiatry, 2004; 161: 1233–46

20. Wagner A, Ruf M, Braus DF, Schmidt MH: Neuropathological changes and body image distortion in anorexia nervosa. Neuroreport, 2003; 14: 2193–97

21. Seeger G, Braus DF, Ruf M et al: Body image distortion reveals amygdala activation in patients with anorexia nervosa – a functional magnetic resonance imaging study. Neurosci Lett, 2002; 326: 25–28

22. Uher R, Murphy T, Friederich HC et al: Functional neuroanatomy of body shape perception in healthy and eating-disordered women. Biol Psychiatry, 2005; 58: 990–97

23. Kurosaki M, Shirao N, Yamashita H et al: Distorted images of one’s own body activates the prefrontal cortex and limbic/paralimbic system in young women: a functional magnetic resonance imaging study. Biol Psychiatry, 2006; 59: 80–86

24. Miyake Y, Okamoto Y, Onoda K et al: Brain activation during the perception of distorted body images in eating disorders. Psychiatry Res, 2010; 181: 183–92

25. Zastrow A, Kaiser S, Stippich C et al: Neural correlates of impaired cognitive-behavioral flexibility in anorexia nervosa. Am J Psychiatry, 2009; 166: 608–16

26. Friederich HC, Herzog W: Cognitive-behavioral flexibility in anorexia nervosa. Curr Top Behav Neurosci, 2011; 6: 111–23

27. Cherkasova MV, Hechtman L: Neuroimaging in attention-deficit hyperactivity disorder: beyond the frontalstriatal circuitry. Can J Psychiatry, 2009; 54: 651–64

28. Emond V, Joyal C, Poissant H: [Structural and functional neuroanatomy of attention-deficit hyperactivity disorder (ADHD)]. Encephale, 2009; 35: 107–14

29. Wang L, LaBar KS, Smolik M et al: Prefrontal mechanisms for executive control over emotional distraction are altered in major depression. Psychiatry Res, 2008; 163: 143–55

30. Barbatul G, Chambon V, Franck N et al: Organization of cognitive control within the lateral prefrontal cortex in schizophrenia. Arch Gen Psychiatry, 2009; 66: 377–86

31. Wessa M, Linke J: Emotional processing in bipolar disorder: behavioural and neuroimaging findings. Int Rev Psychiatry, 2009; 21: 357–67

32. Oberndorfer TA, Kaye WH, Simmons AN et al: Demand-specific alteration of medial prefrontal cortex response during an inhibition task in recovered anorexic women. Int J Eat Disord, 2011; 44: 1–8

33. Lock J, Garrett A, Breenaker J, Reiss AL: Aberrant brain activation during a response inhibition task in adolescent eating disorder subtypes. Am J Psychiatry, 2011; 168: 55–64

34. Schulte-Rether M, Mainz V, Fink GR et al: Theory of mind and the brain in anorexia nervosa: relation to treatment outcome. J Am Acad Child Adolesc Psychiatry, 2012; 51: 832–41

35. Kaye WH, Wierenga CE, Bailer UF et al: Nothing tastes as good as skin-ny feels: the neurobiology of anorexia nervosa. Trends Neurosci, 2013; 36: 110–20

36. Brooks SJ, O’Daly OG, Uher R et al: Differential neural responses to food images in women with bulimia versus anorexia nervosa. PloS One, 2011; 6: e22259

37. Brooks SJ, O’Daly OG, Uher R et al: Thinking about eating food activates visual cortex with reduced bilateral cerebellar activation in females with anorexia nervosa: an fMRI study. PloS One, 2012; 7: e34000

38. Oldershaw A, Treasure J, Hambrook D et al: Is anorexia nervosa a version of autism spectrum disorders? Eur Eat Disord Rev, 2011; 19: 462–74

39. Kaye WH, Frank GK, Bailer UF et al: Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies. Physiol Behav, 2005; 85: 73–81

40. Kaye WH, Bailer UF, Frank GK et al: Brain imaging of serotonin after recovery from anorexia and bulimia nervosa. Physiol Behav, 2005; 86: 15–17

41. Bailer UF, Kaye WH: Serotonin: imaging findings in eating disorders. Curr Top Behav Neurosci, 2011; 6: 59–79

42. Frank GK, Bailer UF, Henry SE et al: Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11C]raclopride. Biol Psychiatry, 2005; 58: 908–12

43. Bailer UF, Frank GK, Price JC et al: Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidance symptoms in anorexia and bulimia nervosa. Psychiatry Res, 2013; 211: 160–68

44. Stefano GB, Krailekova M, Pucci R et al: Low dose morphine adjuvant therapy for enhanced efficacy of antipsychotic drug action. Potential involvement of endogenous morphine in the pathophysiology of schizophrenia. Med Sci Monit, 2012; 18(7): HY23–26

45. Bralet MC, Navarre M, Eskinazi AM et al: [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. Encephale, 2008; 34: 557–62

46. Minzenberg MJ, Laird AR, Thelen S et al: Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry, 2009; 66: 811–22

47. Semkovska M, Bedard MA, Stip E: [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives]. Encephale, 2001; 27: 405–13

48. Stip E: [Cognition, schizophrenia and the effect of antipsychotics]. Encephale, 2006; 32: 341–50

49. Kaye WH, Wierenga CE, Bailer UF et al: Does a Shared Neurobiology for Foods and Drugs of Abuse Contribute to Extremes of Food Ingestion in Anorexia and Bulimia Nervosa? Biol Psychiatry, 2013; 73(9): 836–42

References:
REVIEW ARTICLES

50. Yamamoto A, Papezova H, Uher R: Modulation of thermal pain perception by stress and sweet taste in women with bulimia nervosa. Neuro Endocrinol Lett, 2009; 30: 237–44

51. Marrazzi MA, Luby ED, Kinzie J et al: Endogenous codeine and morphine in anorexia and bulimia nervosa. Life Sci, 1997; 60: 1741–47

52. Kmoch V, Papezova H, Yamamoto A: Two patients with eating disorders treated by naltrexone. Neuro Endocrinol Lett, 2009; 30: 327–30

53. Holanova P, Papezova H, Sekot M: Addiction to analgesic on Eating Disorders, 2013; B20

54. Giuliano C, Robbins TW, Nathan PJ et al: Inhibition of opioid transmission at the mu-opioid receptor prevents both food seeking and binge-like eating. Neuropsychopharmacology, 2012; 37: 2643–52

55. Bandelow B, Schmahl C, Falkai P, Wedekind D: Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev, 2010; 117: 623–36

56. Stefano GB, Ptacek R, Kuzelova H, Kream RM: Endogenous morphine: Up-to-date review 2011. Folia Biolo (Praha), 2012; 58: 49–56

57. Stefano GB, Kream RM: Reciprocal regulation of cellular nitric oxide formation by nitric oxide synthase and nitrite reductases. Med. Sci Monit, 2011; 17(10): RA221–26

58. Bianchi E, Guarna M, Tagliamonte A: Immunocytochemical localization of endogenous codeine and morphine. Adv Neuroimmunol, 1994; 4: 83–92

59. Laux A, Muller AH, Miehe M et al: Mapping of endogenous morphine-like compounds in the adult mouse brain: Evidence of their localization in astrocytes and GABAergic cells. J Comp Neurol, 2011; 519: 2390–416

60. Haukzel H, Muller HW, Herzog H, Grandt R: Cognition-induced modulation of serotonin in the orbitofrontal cortex: a controlled cross-over PET study of a delayed match-to-sample task using the 5-HT2a receptor antagonist [18F]altanserin. Neuroimage, 2011; 58: 905–11

61. Rasmussen H, Erritzoe D, Andersen R et al: Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry, 2010; 67: 9–16

62. Lopez-Cimenez JF, Vilarto MT, Milligan G: Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation. Mol Pharmacol, 2008; 74: 1278–91